Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948975 | 1.00 | TRPV4 (0.52) | TRPV4SLC40A1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL31190599 | 0.84 | ALDH1A1 (0.40) | TRPV4SLC40A1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL3701877 | 0.79 | KDM4E (0.57) | TRPV4SLC40A1ALDH1A1CYP2C9SLC22A6 | |
| SCHEMBL30845950 | 0.79 | TRPV4 (0.52) | TRPV4SLC40A1TDP1CYP2C9SLC22A6 | |
| SCHEMBL5077871 | 0.79 | TRPV4 (0.52) | TRPV4SLC40A1ALDH1A1CYP2C9SLC22A6 | |
| SCHEMBL18231250 | 0.79 | KCNH2 (0.55) | TRPV4SLC40A1CYP2C9SLC22A6SLC22A8 | |
| SCHEMBL2169084 | 0.79 | TRPV4 (0.52) | TRPV4SLC40A1TDP1CYP2C9SLC22A6 | |
| SCHEMBL5077872 | 0.78 | KDM4E (0.55) | TRPV4SLC40A1ALDH1A1CYP2C9SLC22A6 | |
| Hydrochloric Acid SCHEMBL29970288 | 0.78 | TRPV4 (0.50) | TRPV4SLC40A1TDP1CYP2C9SLC22A6 | |
| Hydrochloric Acid SCHEMBL27930121 | 0.78 | KDM4E (0.55) | TRPV4SLC40A1ALDH1A1CYP2C9SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025049643-A1 | NOX4 INHIBITORS AND METHODS OF MAKING AND USING SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024012496-A1 | CANNABINOID RECEPTOR COMPOUND AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-01-18 | — | — | WO | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010028213-A2 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009152082-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
| CN-101501032-A | Fused tricyclic sulfonamides as gamma secretase inhibitors | ELAN PHARM INC (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2038280-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NCOA3 | TRPV4 1558/4885SLC40A1 3005/4885ALDH1A1 4262/4885 |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | TRPV4 4535/4885SLC40A1 1409/4885ALDH1A1 3076/4885 |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | PSEN1, PSEN2, SULT1E1 | TRPV4 3541/4885SLC40A1 1633/4885ALDH1A1 2383/4885 |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | TRPV4 1593/4885SLC40A1 3170/4885ALDH1A1 4042/4885 |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | TRPV4 1305/4885SLC40A1 3369/4885ALDH1A1 3798/4885 |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | TRPV4 4709/4885SLC40A1 4293/4885ALDH1A1 1779/4885 |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | CHRM5, CHRM1, CHRM2 | TRPV4 2619/4885SLC40A1 3993/4885ALDH1A1 557/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | TRPV4 1172/4885SLC40A1 3253/4885ALDH1A1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.